Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 41-46

  Hortobagyi, Gabriel N ^a   Perez, Edith A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; METASTASIS; PRIORITY JOURNAL; UNITED STATES;

EID: 0035170656     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28549     Document Type: Conference Paper

References (34)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer
3. The biology of erbB-2/neu/HER-2 and its role in cancer
4. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
5. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
6. First-line nonhormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
7. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
8. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2overexpressing metastatic breast cancer
9. Polychemotherapy for early breast cancer: An overview of the randomised trials
10. Tamoxifen for early breast cancer: An overview of the randomized trials
11. Ovarian ablation in early breast cancer: Overview of the randomised trials
12. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer
13. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
14. Risk factors for doxorubicin-induced congestive heart failure
15. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
16. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicincontaining therapy
17. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
18. Doxorubicin/ Taxol versus doxorubicin/cyclophosphamide as first line chemotherapy in metastatic breast cancer: A phase III study
19. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
20. A prospective; randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13
21. Overview of the trastuzumab (Herceptin) antiHER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
22. Cardiotoxicity in patients receiving trastuzumab: Primary toxicity, synergistic or sequential stress or surveillance artifact?
23. Phase II pilot study of Herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-neu proto-oncogene. A pilot study of the UCLA Network
24. HER2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer
25. HER2 expression and anthracycline effect: Results from the Naples GUN3 randomized trial
26. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
27. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
28. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
29. Adjuvant chemotherapy: Taxanes - The "Pro" position
30. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
31. Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer